Compare Charles River Laboratories Intl. Inc (CRL) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Norfolk Southern Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $226.38 (market cap $11.14B), while Norfolk Southern Corporation trades at $324.72 (market cap $73.40B). The key difference: Norfolk Southern Corporation is far larger — about 6.6× Charles River Laboratories Intl. Inc's market cap, and Norfolk Southern Corporation pays a 1.65% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | NSC | |
|---|---|---|
Market Cap | $11.14B | $73.40B |
Sector | Health | Technology |
52-Week High | $233.60 | $327.59 |
52-Week Low | $145.57 | $259.49 |
Enterprise Value | $14.00B | $89.16B |
Dividend Yield | — | 1.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Norfolk Southern (NSC) trades at $327.59, up 0.04% on the day, with a bullish technical outlook driven by moving averages and a consensus price target of $344.40. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on July 23, 2026. Strong profitability is evident with a 21.91% net income margin and 17.6% ROE, though valuation multiples like a P/E of 27.53 are elevated. Recent news highlights the ongoing merger review with Union Pacific, a key regulatory focus.
NSC offers steady earnings growth and dividend income, but risks include regulatory hurdles for the merger and rich valuations limiting near-term upside. Analyst sentiment is mixed with 44% buy ratings, suggesting cautious optimism amid merger uncertainty. The stock's proximity to its 52-week high warrants monitoring for pullbacks to support levels near $323.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
